GlassScriptPhysician profile
Thomas P Miller
NPI 1639480221
$1,474.09
in general payments reported to CMS, 2019-2025
18 companies · $61.95 in 2025
The $61.95 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $234 · 2021: $19.77 · 2022: $391 · 2023: $17.67 · 2024: $280 · 2025: $61.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $210.95 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $197.43 | 2022-2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $173.21 | 2019-2023 | Nucala |
| Janssen Pharmaceuticals, INC | $170.65 | 2019-2022 | |
| Medtronic Vascular, INC. | $124.99 | 2019 | |
| Abiomed | $119.06 | 2024 | Impella |
| Cardiovascular Systems INC. | $102.17 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.47 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $61.63 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.72 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.33 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $28.91 | 2022 | |
| Cordis US Corp. | $26.51 | 2025 | Mynx Control Venous |
| Pfizer INC. | $24.28 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $17.73 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $16.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.93 | 2019 | |
| Amgen INC. | $11.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.